Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis

Laila M. Poisson, Hamid Suhail, Jaspreet Singh, Indrani Datta, Aleksandar Deni, Krzysztof Labuzek, MD Nasrul Hoda, Ashray Shankar, Ashok Kumar, Mirela Cerghet, Stanton Elias, Robert P. Mohney, Moses Rodriguez, Ramandeep Rattan, Ashutosh K. Mangalam, Shailendra Giri

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We performed untargeted metabolomics in plasma of B6 mice with experimental autoimmune encephalitis (EAE) at the chronic phase of the disease in search of an altered metabolic pathway(s). Of 324 metabolites measured, 100 metabolites that mapped to various pathways (mainly lipids) linked to mitochondrial function, inflammation, and membrane stability were observed to be significantly altered between EAE and control (p > 0.05, false discovery rate >0.10). Bioinformatics analysis revealed six metabolic pathways being impacted and altered in EAE, including <-linolenic acid and linoleic acid metabolism (PUFA). The metabolites of PUFAs, includingω-3 andω-6 fatty acids, are commonly decreased in mouse models of multiple sclerosis (MS) and in patients with MS. Daily oral administration of resolvin D1, a downstream metabolite ofω-3, decreased disease progression by suppressing autoreactive T cells and inducing an M2 phenotype of monocytes/macrophages and resident brain microglial cells. This study provides a proof of principle for the application of metabolomics to identify an endogenous metabolite(s) possessing drug-like properties, which is assessed for therapy in preclinical mouse models of MS.

Original languageEnglish (US)
Pages (from-to)30697-30712
Number of pages16
JournalJournal of Biological Chemistry
Volume290
Issue number52
DOIs
StatePublished - Dec 25 2015

Fingerprint

Metabolomics
Metabolites
Multiple Sclerosis
Animals
Animal Models
Metabolic Networks and Pathways
Plasmas
Pharmaceutical Preparations
Computational Biology
Oral Administration
Disease Progression
Monocytes
Chronic Disease
Fatty Acids
Macrophages
T-cells
Inflammation
T-Lymphocytes
Phenotype
Lipids

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis. / Poisson, Laila M.; Suhail, Hamid; Singh, Jaspreet; Datta, Indrani; Deni, Aleksandar; Labuzek, Krzysztof; Hoda, MD Nasrul; Shankar, Ashray; Kumar, Ashok; Cerghet, Mirela; Elias, Stanton; Mohney, Robert P.; Rodriguez, Moses; Rattan, Ramandeep; Mangalam, Ashutosh K.; Giri, Shailendra.

In: Journal of Biological Chemistry, Vol. 290, No. 52, 25.12.2015, p. 30697-30712.

Research output: Contribution to journalArticle

Poisson, LM, Suhail, H, Singh, J, Datta, I, Deni, A, Labuzek, K, Hoda, MDN, Shankar, A, Kumar, A, Cerghet, M, Elias, S, Mohney, RP, Rodriguez, M, Rattan, R, Mangalam, AK & Giri, S 2015, 'Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis', Journal of Biological Chemistry, vol. 290, no. 52, pp. 30697-30712. https://doi.org/10.1074/jbc.M115.679068
Poisson, Laila M. ; Suhail, Hamid ; Singh, Jaspreet ; Datta, Indrani ; Deni, Aleksandar ; Labuzek, Krzysztof ; Hoda, MD Nasrul ; Shankar, Ashray ; Kumar, Ashok ; Cerghet, Mirela ; Elias, Stanton ; Mohney, Robert P. ; Rodriguez, Moses ; Rattan, Ramandeep ; Mangalam, Ashutosh K. ; Giri, Shailendra. / Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis. In: Journal of Biological Chemistry. 2015 ; Vol. 290, No. 52. pp. 30697-30712.
@article{0c27af47468e464380572cbd6670e666,
title = "Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis",
abstract = "We performed untargeted metabolomics in plasma of B6 mice with experimental autoimmune encephalitis (EAE) at the chronic phase of the disease in search of an altered metabolic pathway(s). Of 324 metabolites measured, 100 metabolites that mapped to various pathways (mainly lipids) linked to mitochondrial function, inflammation, and membrane stability were observed to be significantly altered between EAE and control (p > 0.05, false discovery rate >0.10). Bioinformatics analysis revealed six metabolic pathways being impacted and altered in EAE, including <-linolenic acid and linoleic acid metabolism (PUFA). The metabolites of PUFAs, includingω-3 andω-6 fatty acids, are commonly decreased in mouse models of multiple sclerosis (MS) and in patients with MS. Daily oral administration of resolvin D1, a downstream metabolite ofω-3, decreased disease progression by suppressing autoreactive T cells and inducing an M2 phenotype of monocytes/macrophages and resident brain microglial cells. This study provides a proof of principle for the application of metabolomics to identify an endogenous metabolite(s) possessing drug-like properties, which is assessed for therapy in preclinical mouse models of MS.",
author = "Poisson, {Laila M.} and Hamid Suhail and Jaspreet Singh and Indrani Datta and Aleksandar Deni and Krzysztof Labuzek and Hoda, {MD Nasrul} and Ashray Shankar and Ashok Kumar and Mirela Cerghet and Stanton Elias and Mohney, {Robert P.} and Moses Rodriguez and Ramandeep Rattan and Mangalam, {Ashutosh K.} and Shailendra Giri",
year = "2015",
month = "12",
day = "25",
doi = "10.1074/jbc.M115.679068",
language = "English (US)",
volume = "290",
pages = "30697--30712",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "52",

}

TY - JOUR

T1 - Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis

AU - Poisson, Laila M.

AU - Suhail, Hamid

AU - Singh, Jaspreet

AU - Datta, Indrani

AU - Deni, Aleksandar

AU - Labuzek, Krzysztof

AU - Hoda, MD Nasrul

AU - Shankar, Ashray

AU - Kumar, Ashok

AU - Cerghet, Mirela

AU - Elias, Stanton

AU - Mohney, Robert P.

AU - Rodriguez, Moses

AU - Rattan, Ramandeep

AU - Mangalam, Ashutosh K.

AU - Giri, Shailendra

PY - 2015/12/25

Y1 - 2015/12/25

N2 - We performed untargeted metabolomics in plasma of B6 mice with experimental autoimmune encephalitis (EAE) at the chronic phase of the disease in search of an altered metabolic pathway(s). Of 324 metabolites measured, 100 metabolites that mapped to various pathways (mainly lipids) linked to mitochondrial function, inflammation, and membrane stability were observed to be significantly altered between EAE and control (p > 0.05, false discovery rate >0.10). Bioinformatics analysis revealed six metabolic pathways being impacted and altered in EAE, including <-linolenic acid and linoleic acid metabolism (PUFA). The metabolites of PUFAs, includingω-3 andω-6 fatty acids, are commonly decreased in mouse models of multiple sclerosis (MS) and in patients with MS. Daily oral administration of resolvin D1, a downstream metabolite ofω-3, decreased disease progression by suppressing autoreactive T cells and inducing an M2 phenotype of monocytes/macrophages and resident brain microglial cells. This study provides a proof of principle for the application of metabolomics to identify an endogenous metabolite(s) possessing drug-like properties, which is assessed for therapy in preclinical mouse models of MS.

AB - We performed untargeted metabolomics in plasma of B6 mice with experimental autoimmune encephalitis (EAE) at the chronic phase of the disease in search of an altered metabolic pathway(s). Of 324 metabolites measured, 100 metabolites that mapped to various pathways (mainly lipids) linked to mitochondrial function, inflammation, and membrane stability were observed to be significantly altered between EAE and control (p > 0.05, false discovery rate >0.10). Bioinformatics analysis revealed six metabolic pathways being impacted and altered in EAE, including <-linolenic acid and linoleic acid metabolism (PUFA). The metabolites of PUFAs, includingω-3 andω-6 fatty acids, are commonly decreased in mouse models of multiple sclerosis (MS) and in patients with MS. Daily oral administration of resolvin D1, a downstream metabolite ofω-3, decreased disease progression by suppressing autoreactive T cells and inducing an M2 phenotype of monocytes/macrophages and resident brain microglial cells. This study provides a proof of principle for the application of metabolomics to identify an endogenous metabolite(s) possessing drug-like properties, which is assessed for therapy in preclinical mouse models of MS.

UR - http://www.scopus.com/inward/record.url?scp=84951763648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951763648&partnerID=8YFLogxK

U2 - 10.1074/jbc.M115.679068

DO - 10.1074/jbc.M115.679068

M3 - Article

VL - 290

SP - 30697

EP - 30712

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 52

ER -